162 related articles for article (PubMed ID: 24812502)
1. Clinical use of aclidinium in patients with COPD.
Reid DJ; Carlson AA
Int J Chron Obstruct Pulmon Dis; 2014; 9():369-79. PubMed ID: 24812502
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
Jones PW; Rennard SI; Agusti A; Chanez P; Magnussen H; Fabbri L; Donohue JF; Bateman ED; Gross NJ; Lamarca R; Caracta C; Gil EG
Respir Res; 2011 Apr; 12(1):55. PubMed ID: 21518460
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
4. The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies.
Jones PW; Leidy NK; Hareendran A; Lamarca R; Chuecos F; Garcia Gil E
Respir Res; 2016 May; 17(1):61. PubMed ID: 27215749
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.
Karabis A; Lindner L; Mocarski M; Huisman E; Greening A
Int J Chron Obstruct Pulmon Dis; 2013; 8():405-23. PubMed ID: 24043936
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.
Beier J; Kirsten AM; Mróz R; Segarra R; Chuecos F; Caracta C; Gil EG
COPD; 2013 Aug; 10(4):511-22. PubMed ID: 23819698
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
Miravitlles M; Chapman KR; Chuecos F; Ribera A; Gil EG
Int J Chron Obstruct Pulmon Dis; 2016; 11():2041-53. PubMed ID: 27621610
[TBL] [Abstract][Full Text] [Related]
8. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease.
Sims MW; Panettieri RA
Int J Chron Obstruct Pulmon Dis; 2011; 6():457-66. PubMed ID: 22003291
[TBL] [Abstract][Full Text] [Related]
9. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.
Buhl R; Banerji D
Int J Chron Obstruct Pulmon Dis; 2012; 7():729-41. PubMed ID: 23118536
[TBL] [Abstract][Full Text] [Related]
10. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).
Bateman ED; Chapman KR; Singh D; D'Urzo AD; Molins E; Leselbaum A; Gil EG
Respir Res; 2015 Aug; 16(1):92. PubMed ID: 26233481
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.
Singh D; Jones PW; Bateman ED; Korn S; Serra C; Molins E; Caracta C; Gil EG; Leselbaum A
BMC Pulm Med; 2014 Nov; 14():178. PubMed ID: 25404569
[TBL] [Abstract][Full Text] [Related]
12. Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies.
Wedzicha JA; Agusti A; Donaldson G; Chuecos F; Lamarca R; Garcia Gil E
COPD; 2016 Dec; 13(6):669-676. PubMed ID: 27159613
[TBL] [Abstract][Full Text] [Related]
13. Dose selection for glycopyrrolate/eFlow
Donohue JF; Goodin T; Tosiello R; Wheeler A
Respir Res; 2017 Dec; 18(1):202. PubMed ID: 29202767
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years.
Karabis A; Mocarski M; Eijgelshoven I; Bergman G
Clinicoecon Outcomes Res; 2014; 6():175-85. PubMed ID: 24741321
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium.
Lopez-Campos JL; Calero C; Lopez-Ramirez C; Asensio-Cruz MI; Márquez-Martín E; Ortega-Ruiz F
Patient Prefer Adherence; 2015; 9():95-104. PubMed ID: 25653503
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study.
Wise RA; Chapman KR; Scirica BM; Schoenfeld DA; Bhatt DL; Daoud SZ; Seoane B; Reisner C; Garcia Gil E
Chronic Obstr Pulm Dis; 2018 Jan; 5(1):5-15. PubMed ID: 29629400
[No Abstract] [Full Text] [Related]
17. Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials.
McGarvey L; Morice AH; Smith JA; Birring SS; Chuecos F; Seoane B; Jarreta D
BMJ Open Respir Res; 2016; 3(1):e000148. PubMed ID: 28074135
[TBL] [Abstract][Full Text] [Related]
18. Symptom variability in COPD: a narrative review.
Lopez-Campos JL; Calero C; Quintana-Gallego E
Int J Chron Obstruct Pulmon Dis; 2013; 8():231-8. PubMed ID: 23687444
[TBL] [Abstract][Full Text] [Related]
19. Effect of repeated Waon therapy on exercise tolerance and pulmonary function in patients with chronic obstructive pulmonary disease: a pilot controlled clinical trial.
Kikuchi H; Shiozawa N; Takata S; Ashida K; Mitsunobu F
Int J Chron Obstruct Pulmon Dis; 2014; 9():9-15. PubMed ID: 24363555
[TBL] [Abstract][Full Text] [Related]
20. COPD: the patient perspective.
Jones PW; Watz H; Wouters EF; Cazzola M
Int J Chron Obstruct Pulmon Dis; 2016; 11 Spec Iss(Spec Iss):13-20. PubMed ID: 26937186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
